Slingshot members are tracking this event:

CHMP Issues Positive Opinion for ORENCIA (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details “This CHMP recommendation is particularly notable because it is the first time that MRI-detected structural and inflammatory measures of disease severity are cited as support for the proposed RA indication,” said Paul Emery, M.A., M.D., F.R.C.P., F.Med.Sci., Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom. “This is consistent with mounting evidence supporting a paradigm shift in how and when we initiate different forms of RA therapy, particularly for those patients with progressive disease accompanied by certain poor prognostic markers.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Methotrexate, Orencia, Abatacept, Rheumatoid Arthritis, High Disease Activity, Methotrexate